Next Article in Journal
Utilization of Pharmacological Ascorbate to Enhance Hydrogen Peroxide-Mediated Radiosensitivity in Cancer Therapy
Next Article in Special Issue
Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review
Previous Article in Journal
Healthy Tissue Damage Following Cancer Ion Therapy: A Radiobiological Database Predicting Lymphocyte Chromosome Aberrations Based on the BIANCA Biophysical Model
Previous Article in Special Issue
Natural Products with Activity against Lung Cancer: A Review Focusing on the Tumor Microenvironment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of Demissidine Analogues from Tigogenin via Imine Intermediates †

Faculty of Chemistry, University of Białystok, K. Ciołkowskiego 1K, 15-245 Białystok, Poland
*
Authors to whom correspondence should be addressed.
Dedicated to Prof. Dr. Ludger Wessjohann on the occasion of his 60th birthday.
Int. J. Mol. Sci. 2021, 22(19), 10879; https://doi.org/10.3390/ijms221910879
Submission received: 18 September 2021 / Revised: 30 September 2021 / Accepted: 5 October 2021 / Published: 8 October 2021

Abstract

:
A five-step transformation of a spiroketal side chain of tigogenin into an indolizidine system present in solanidane alkaloids such as demissidine and solanidine was elaborated. The key intermediate in the synthesis was spiroimine 3 readily obtained from tigogenin by its RuO4 oxidation to 5,6-dihydrokryptogenin followed by amination with aluminum amide generated in situ from DIBAlH and ammonium chloride. The mild reduction of spiroimine to a 26-hydroxy-dihydropyrrole derivative and subsequent mesylation resulted in the formation of 25-epidemissidinium salt or 23-sulfone depending on reaction conditions.

1. Introduction

Demissidine and solanidine are the main representatives of the solanidane alkaloids that occur mainly as glycosides in potato species including Solanum tuberosum, Solanum demissum, and Solanum acaule (Figure 1) [1,2]. The various biological properties of these cholestane alkaloids have been reported in the literature [3]. Among these, α-solanine and α-chaconine, two main solanidine glycosides, are potent enough to inhibit proliferation and induce apoptosis in various types of cancer cells including cervical, liver, lymphoma, and stomach cancer cells [4]. The effectiveness of α-chaconine against hepatocellular cancer HepG2 cells is higher than the common anticancer agents doxorubicin and camptothecin [5]. Additionally, demissidine and its natural glycoside, commersonine, inhibit the growth of human colon and liver cancer cells in culture [5]. Apart from showing antitumor activity, solanidane-type alkaloids are known to act as natural insect deterrents, have antimicrobial and anti-inflammatory properties, inhibit acetylcholinesterase, and disrupt cell membranes [3,6,7,8,9]. Additionally, studies of solanidine and demissidine analogues confirm their potency for the design of new pharmacologically active agents [10,11,12].
So far, eight syntheses of solanidine and demissidine have been described, four of them in the last decade, and the latest one was reported last year [13,14,15,16,17,18,19,20]. Although recently invented methods brought a significant improvement, the described methods suffer from several drawbacks, such as multi-step procedures or unsatisfactory yields. Moreover, they cannot be easily adapted to the synthesis of demissidine or solanidine analogues. Therefore, the elaboration of an efficient route to demissidine congeners is still needed. An improved approach to the synthesis of different demissidine stereoisomers has been recently reported [21]. Here, we propose an alternative strategy toward demissidine analogues from an easily available steroid sapogenin—tigogenin.

2. Results and Discussion

We found that a convenient intermediate for the transformation of the spiroketal system present in steroidal sapogenins, e.g., tigogenin, into the solanidane framework of demissidine was spiroimine 3, shown in Scheme 1. This novel spirostane aza-analogue was obtained from tigogenin by a two-step protocol involving tigogenin oxidation to a 5,6-dihydrokryptogenin derivative and its reaction with aluminum amide as an aminating agent.
The most convenient method for the oxidative cleavage of sapogenin spiroketal to hydroxy-diketone was chosen first. After perusing the known literature protocols [22,23,24,25], we employed the RuO4/NaIO4 catalytic system. The desired 5,6-dihydrokryptogenin derivative was obtained by the oxidation of tigogenin 3-TBS ether (1) as a mixture of two tautomers 2a and 2b in 71% yield. In the next step, the obtained product was subjected to a reaction with aluminum amide generated in situ from diisobutylaluminum hydride (DIBAlH) and ammonium salt. The use of various aminoalanes as aminating agents for such compounds as epoxides, ketones, carboxylic acids, and their derivatives (chlorides, esters) has previously been widely reported in the literature [26,27,28,29,30,31]. Our previous investigations have shown that the desired aminoalane might be readily synthesized by the treatment of DIBAlH with ammonium chloride under mild reaction conditions (0 °C – room temperature, THF, up to 2 h) [32]. However, the reagent proved to be unstable and its structure was not definitely determined. The reaction of the 2a/2b mixture with aminoalane prepared as described above was carried out in refluxing THF/toluene (Scheme 1). Spiroimine 3 was obtained as the main reaction product (44%) when using aluminum amide prepared in situ from 40 equivalents of DIBAlH and 42 equivalents of ammonium chloride. It is worth noting that this compound was not formed in the absence of DIBAlH. Compound 3 was accompanied by two minor products, imine 4 (12%) and enone 5 (5%). Ketone 5 was produced as a result of an aldol condensation probably due to enolization caused by aluminum amide playing a role as a Lewis acid. The formation of imine 4 in the experiment was unexpected and difficult to explain in terms of the substrate 2a/2b reaction with prepared aminoalane. It seems that some unreacted diisobutylaluminum hydride was still present in the reaction mixture, resulting in the reduction of initially produced spiroimine 3 to 4 (vide infra). The reaction of compounds 2a and 2b with aminoalane prepared from a lower amount of DIBAlH led to the incomplete conversion. For example, employing the aminating reagent produced from 20 equivalents of DIBAlH, imine 3 was obtained in 26% yield only, while the α,β-unsaturated ketone 5 was produced in 25% yield. In this case, compound 4 was not isolated. Both imines, 3 and 4, appeared to be convenient substrates for the synthesis of solasodine or solanidine derivatives. The mild reduction of spiroimine should provide hitherto unknown ‘reverse’ spirosolanes with the nitrogen atom in the pyrrolidine E-ring and the oxygen atom in the ‘pyranose’ F-ring. Moreover, the reductive cleavage of the spiroimine F-ring may open a direct way to solanidane alkaloids possessing an indolizidine moiety.
First, the reduction of compound 3 under mild conditions was attempted. Interestingly, the expected hemiaminal 6 (Scheme 2) was not obtained, though various reducing agents were examined. Using an equimolar amount of various borohydrides, such as NaBH4, NaBH4/I2, and NaBH3CN, under different conditions (temperature, reaction times), the main isolated product was always imine 4 accompanied by small amounts of pyrrolidine 7. The other examined reducing agents (DIBAlH, H2/PtO2, H2/Pd, Hantzsch ester/TFA [33], TESH/acid) proved less effective.
The above-described results of the reduction experiments pointed out that compound 6 is less stable than its open-chain isomer 4 (confirmed by calculations). This explains unsuccessful attempts of imine 4 cyclization to 6 in the presence of acids. The observed behavior of imine 4 is clearly different from that of ‘pseudosapogenins’, which readily cyclize to spiroketals. The latter are relatively stable compounds, though their F-ring opening occurs when they are treated with strong Lewis acids. The natural aza-analogues of spirostanes (spirosolanes) containing the nitrogen atom in ring F, e.g., solasodine or tomatidine, are even more susceptible to an electrophilic attack than spiroketals. However, in the case of spirosolanes, the ‘furanose’ E-ring is readily opened [34]. This is because the cation resulting from the C–O bond cleavage is stabilized by electrons of the neighboring nitrogen atom. It seems that the isomeric compounds containing the nitrogen atom in the E-ring undergo the opening of the ‘pyranose’ F-ring for the same reason. The cleavage of the oxygen-containing ring in spirosolanes was also observed under the reducing conditions [35,36]. Despite the failure to obtain a ‘reverse’ spirosolane analogue from imine 3, it still seemed to be a convenient intermediate for the synthesis of solanidane alkaloids. A derivative of imine 4 was previously employed by Uhle and Tian to build an indolizidine system. In the solanidine analogue synthesis reported by Uhle [37], the imine was obtained in 20% yield from kryptogenin 16-(2,4-dinitrophenyl)hydrazone and transformed into 25-episolanidine by refluxing with KOH in ethylene glycol in 65% yield. In 2016, Tian and coworkers [18] developed a new way to synthesize solanidine and demissidine using diosgenin or tigogenin as a starting material, respectively. In the method proposed by the Chinese group, 26-methyl ester 22-imine was prepared in five steps and further transformed into the desired alkaloid by the selective reduction of the imine moiety to pyrrolidine, spontaneous intramolecular aminolysis of the obtained amino-ester to lactam, and reduction. The use of spiroimine 3 as an intermediate for the construction of an indolizidine unit allowed us to shorten the solanidane synthesis from tigogenin. The approach explored in our study involved the reduction of spiroimine 3 to dihydropyrrole 4 followed by its cyclization and reduction. As our initial studies on the imine reduction showed that only complex borohydrides were effective for this transformation, we went on to optimize the reduction reaction conditions using NaBH4 and NaBH3CN as reducing agents. Our results are summarized in Table 1. Apart from compound 4, in most cases a small amount of amine 7 was formed. Imine 4 was obtained in the best yield in reaction with a NaBH4/I2 system (entry 5). With 1 equivalent of NaBH4 (without any additives or with AcONa) at a low temperature and controlling the reaction time, we restrained imine over-reduction and obtained compound 4 in good yield (entry 2, 3, 4). NaBH3CN was less efficient (entry 6, 7). Additionally, when NaBH3CN was used in the presence of AcOH, an imine–cyanoborane complex 8 was formed (Figure 2).
We envisaged that the activation of the 26-hydroxyl group in compound 4 would result in spontaneous ring closing to iminium salt. Therefore, we subjected compound 4 to a reaction with mesyl chloride. As examples of the successful chemoselective mesylation of the primary hydroxyl group in the presence of amine function could be found in the literature [38,39,40], we supposed that the chemoselective mesylation of hydroxy-imine should be reached under similar conditions. The initial mesylation of hydroxy-imine 4 carried out with 1.2 equivalents of mesyl chloride in the presence of triethylamine at −15 °C resulted mainly in a less polar product (26-mesyloxy-imine), which spontaneously cyclized after work-up to the desired iminium salt 9 (Scheme 3). Under mesylation conditions, TBS protection of the 3-OH group was also removed and the indolizinium salt 9 was isolated in 45% yield. Compound 9 was readily transformed into 25-epidemissidine (10) by reduction with NaBH4.
Conducting the mesylation under slightly harsher conditions (1.2 equiv. of MsCl, Et3N, 0 °C or 2 equiv. of MsCl, Py, DMAP(cat.), 0 °C–room temp.) led to a complex mixture of products. The iminium salt was formed only in 5% yield, while the main reaction product was identified as an enamine N,O-dimesyl derivative 11a or 11b (Figure 3).
As the changes made did not result in the yield improvement of the desired indolizinium salt, we also attempted to improve the chemoselectivity of O-mesylation by deactivating the imine nitrogen. For this purpose, hydroxy-imine 4 was reacted with hydrogen chloride (generated in situ from AcCl and MeOH) to obtain imine hydrochloride before mesylation. The crude salt without isolation was subjected to mesylation with 2 equivalents of MsCl in the presence of Et3N at 0 °C–room temp. To our surprise, after basic work-up sulfone 12 (Scheme 4) was isolated, instead of the expected indolizinium salt 9. The obtained solanidane seems to be a valuable intermediate for the synthesis of leptinidine analogues.
The hypothetical mechanism of sulfone formation is outlined in Scheme 5. An addition of HCl caused the tautomerization of imine to enamine (I) via the in situ formation of iminium salt and simultaneous deprotection of TBS ether. The enamine (I) possessing three nucleophilic sites, primary OH group, secondary OH group, and enamine carbon atom, reacted further with mesyl chloride. Apart from alcohol mesylation (II), the mesylation of an enamine electron-rich carbon occurred, leading to sulfone formation with the reconstruction of imine in ring E (III). In the final step, the cyclization to indolizine took place via an intramolecular nucleophilic substitution of 26-mesylate with the imine nitrogen. The sequence of the last-mentioned transformations (the sulfone formation followed by the ring closing) is not obvious. The reverse order of transformations (with the cyclization first) is less likely but could not be excluded. It should be mentioned that a small amount of sulfone was also formed in the mesylation of imine 4 without pre-addition of HCl.
The novel compounds prepared within the study, including the imine intermediates that frequently show antibiotic activity [41], will be subjected to biological activity evaluation in due course.

3. Materials and Methods

3.1. General

NMR spectra were recorded with Bruker Avance II 400 spectrometer operating at 400 MHz, using CDCl3 solutions with TMS as the internal standard (only selected signals in the 1H NMR spectra are reported). Coupling constants (J) are given in Hz. The spectra of compounds 3–10 and 12 are included in the Supplementary Materials. The FTIR spectra were obtained using Nicolet™ 6700 spectrometer (Thermo Scientific, Waltham, MA, USA). The spectra were recorded in the range between 4000 and 500 cm−1 with a resolution of 4 cm−1 and 32 scans using Attenuated Total Reflectance (ATR) techniques. ESI and ESI-HRMS spectra were obtained on the Agilent 6530 Accurate-Mass Q-TOF ESI and LC/MS system. Melting points were determined using MP70 Melting Point System (Mettler Toledo, Greifensee, Switzerland). Thin-layer chromatography (TLC) was performed on aluminum plates coated with silica gel 60 F254 (Merck, Darmstadt, Germany), by spraying with ceric ammonium molybdate (CAM) solution, followed by heating. The reaction products were isolated by column chromatography, performed using 70–230 mesh silica gel (J. T. Baker).

3.2. Chemical Synthesis

3.2.1. Oxidation of 3-TBS Tigogenin (1) with RuO4/NaIO4

Solution of NaIO4 (1.8 g, 8.4 mmol) and RuO2 (23 mg, 0.17 mmol) in the mixture of water (20 mL), acetone (10 mL), and tetrachloride (20 mL) was vigorously stirred until the yellow color of RuO4 appeared. Then, a solution of 3-TBS tigogenin (1, 0.3 g, 0.57 mmol) in 8 mL of CCl4 was added in three portions and the reaction mixture was stirred for 10 h at room temperature. After that time, the TLC control showed that no starting material remained. A few drops of isopropanol were added to quench RuO4 and the resulting slurry was stirred for an additional 10 min at room temperature (yellow RuO4 turned into black RuO2). The reaction mixture was poured into water and product was extracted with CHCl3. The extract was dried over anhydrous sodium sulfate, and the solvent was evaporated. Silica gel column chromatography afforded the product as an equilibrium mixture of two tautomers 2a and 2b, identical to that described in reference [42] in 73% total yield.
Compound 2a/2b, eluted with 7.5% to 25% AcOEt/hexane: for main tautomer: 1H NMR (400 MHz, CDCl3) δ 3.58 (m, 2H), 3.47 (m, 1H), 2.57 (m, 1H), 2.62 (m, 1H), 1.02 (d, J = 7.0, 3H), 0.95 (d, J = 6.6, 3H), 0.89 (s, 9H), 0.81 (s, 3H), 0.74 (s, 3H), 0.06 (s, 6H); ESI-MS 547 [M+H]+. HRMS calculated for C33H59O4Si (M+H)+, 547.4177; found 547.4230.

3.2.2. Synthesis of (25R)-3β-t-butyldimethylsililoxy-16-aza-spirost-16(N)-ene (3)

Preparation of the aminoalane reagent from DIBALH and NH4Cl
A solution of DIBAlH in toluene (1 M, 22 mL, 22 mmol, 40 equiv. relative to compounds 2a and 2b) was added to a cooled (0–5 °C) suspension of NH4Cl (1.23 g, 23 mmol, 42 equiv.) in anhydrous THF (15 mL) under argon. The reaction was stirred for 15 min in an ice bath and then 1.5 h at room temperature. After this time, the obtained reagent solution was used directly for the reaction with compound 2a/2b.
Synthesis of imine 3
The solution of aminoalane reagent (prepared from 40 equiv. of DIBAlH) was added dropwise to a solution of compound 2a and 2b (0.3 g, 0.549 mmol) in anhydrous THF (ca 6 mL) at room temperature. Then, stirring was continued for 16 h at reflux. After this time, the reaction mixture was cooled, quenched with aqueous solution of KHSO4, and the product was extracted with ether. The extract was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated. Silica gel column chromatography afforded three products: spiroimine 3 (44%) eluted with 10% AcOEt/hexane, α,β-unsaturated ketone 5 (5%) eluted with 15% AcOEt/hexane, and dihydropyrrole 4 (12%) eluted with 70% AcOEt/hexane.
Compound 3: 1H NMR (400 MHz, CDCl3) δ 3.56 (m, 2H), 3.45 (dd, J = 11.0, 10.9, 1H), 2.56 (m, 1H), 2.45 (m, 1H), 1.01 (d, J = 6.9, 3H), 0.89 (s, 9H), 0.84 (d, J = 6.6, 3H), 0.83 (s, 3H), 0.61 (s, 3H), 0.06 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 193.2 (C), 107.6 (C), 72.1 (CH), 70.6 (CH), 69.1 (CH2), 56.8 (CH), 54.5 (CH), 45.0 (CH), 42.7 (CH), 39.8 (C), 38.6 (CH2), 38.3 (CH2), 37.0 (CH2), 35.7 (C), 35.1 (CH), 33.7 (CH2), 32.3 (CH2), 31.9 (CH2), 30.8 (CH), 29.3 (CH2), 28.7 (CH2), 28.5 (CH2), 25.9 (3xCH3), 20.9 (CH2), 18.3 (C), 17.2 (CH3), 13.5 (CH3), 12.43 (CH3), 12.39 (CH3), −4.6 (2xCH3); ESI-MS 528 [M+H]+. HRMS calculated for C33H59NO2Si (M+H)+, 528.4231; found 528.4297; IR ATR, νmax (cm−1): 1728, 1667, 1457, 1373, 1248, 1173, 1063.
Compound 4: 1H NMR (400 MHz, CDCl3) δ 4.43 (m, 1H), 3.55 (m, 1H), 3.43 (dd, J = 11.1, 4.0, 1H), 3.30 (dd, J = 11.1, 6.0, 1H), 2.61 (q, J = 7.3, 1H), 2.29 (m, 2H), 2.22 (m, 1H), 1.08 (d, J = 7.3, 3H), 0.92 (d, J = 6.3, 3H), 0.89 (s, 9H), 0.79 (s, 3H), 0.51 (s, 3H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 182.0 (C), 74.8 (CH), 72.1 (CH), 65.9 (CH2), 61.6 (CH), 54.9 (CH), 54.6 (CH), 45.0 (CH), 44.5 (CH), 41.4 (C), 39.2 (CH2), 38.6 (CH2), 37.2 (CH2), 35.9 (CH), 35.6 (C), 35.1 (CH), 32.4 (CH2), 32.0 (CH2), 31.9 (CH2), 28.7 (CH2), 27.6 (CH2), 27.5 (CH2), 25.9 (3xCH3), 20.8 (CH2), 18.8 (CH3), 18.3 (C), 17.0 (CH3), 14.0 (CH3), 12.4 (CH3), −4.6 (2xCH3); ESI-MS 530 [M+H]+. HRMS calculated for C33H60NO2Si (M+H)+, 530.4388; found 530.4398; IR ATR, νmax (cm−1): 3235, 1631, 1454, 1372, 1250, 1095, 1062.
Compound 5: 1H NMR (400 MHz, CDCl3) δ 3.57 (m, 1H), 3.47 (m, 1H), 3.37 (m, 1H), 3.12 (m, 1H), 2.58 (m, 1H), 2.39 (dd, J = 13.5, 5.6, 1H), 2.24 (bs, 1H), 2.17 (q, J = 7.2, 1H), 1.19 (d, J = 7.2, 3H), 0.89 (s, 9H), 0.83 (s, 3H), 0.80 (d, J = 6.8, 3H), 0.54 (s, 3H), 0.06 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 214.9 (C), 183.9 (C), 134.1 (C), 72.0 (CH), 66.0 (CH2), 65.8 (CH), 55.9 (CH), 54.7 (CH), 45.0 (CH), 42.8 (CH), 41.2 (C), 38.6 (CH2), 37.9 (CH2), 37.1 (CH2), 35.7 (C), 35.2 (CH), 35.0 (CH), 32.2 (CH2), 31.9 (CH2), 28.5 (CH2), 28.0 (CH2), 26.2 (CH2), 25.9 (3xCH3), 20.9 (CH2), 18.3 (C), 16.4 (CH3), 14.5 (CH3), 12.4 (CH3), 12.3 (CH3), -4.6 (2xCH3); ESI-MS 529 [M+H]+. HRMS calculated for C33H57O3Si (M+H)+, 529.4071; found 529.4062; IR ATR, νmax (cm−1): 3431, 1697, 1654, 1456, 1373, 1248, 1080, 834, 772.

3.2.3. General Procedure for Imine 3 Reduction with Complex Sodium Hydride

To the stirred solution of imine 3 (1 equiv.) in the proper solvent, reducing agents (NaBH4, NaBH3CN) and additives (NaOAc, I2, AcOH) were added. The detailed reaction conditions are indicated in Table 1. The reaction mixture was monitored by TLC. The reaction mixture was poured into water and extracted with CHCl3. The extract was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated. The crude products (4, 7, 8) were isolated by silica gel column chromatography.
Compound 7, eluted with 8% MeOH/CHCl3: 1H NMR (400 MHz, CDCl3) δ 3.75 (m, 1H), 3.51 (m, 2H), 3.37 (m, 1H), 2.88 (m, 1H), 2.01 (m, 1H), 1.01 (d, J = 6.4, 3H), 0.88 (s, 9H), 0.864 (s, 3H), 0.859 (d, J = 6.3, 3H), 0.80 (s, 3H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 72.1 (CH), 70.4 (CH), 67.3 (CH2), 63.2 (CH), 62.2 (CH), 57.6 (CH), 54.3 (CH), 45.0 (CH), 41.2 (C), 40.0 (CH2), 38.6 (CH2), 38.4 (CH), 37.1 (CH2), 35.6 (C), 34.8 (CH), 34.7 (CH), 32.3 (CH2), 31.9 (CH2), 30.8 (CH2), 29.6 (CH2), 28.6 (CH2), 27.9 (CH2), 25.9 (3xCH3), 20.9 (CH2), 18.2 (CH3), 18.1 (C), 17.0 (CH3), 16.0 (CH3), 12.3 (CH3), −4.6 (2xCH3); ESI-MS 532 [M+H]+. HRMS calculated for C33H62NO2Si (M+H)+, 532.4544; found 532.4559; IR ATR, νmax (cm−1): 3288, 1454, 1368, 1247, 1092.
Compound 8 (obtained by reduction with NaBH3CN, Table 1, entry 6), eluted with 45% AcOEt/hexane: 1H NMR (400 MHz, CDCl3) δ 4.66 (m, 1H), 3,62–3.50 (m, 3H), 3.07 (q, J = 7.4, 1H), 2.91 (dd, J = 12.4, 4.3, 1H), 2.48–2.35 (m, 2H), 1.83 (d, J = 8.4, 1H), 1.22 (d, J = 7.4, 3H), 1.00 (d, J = 6.6, 3H), 0.89 (s, 9H), 0.79 (s, 3H), 0.57 (s, 3H), 0,05 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 191. 4 (C), 76.9 (CH), 72.0 (CH), 66.7 (CH2), 57.6 (CH), 54.4 (CH), 54.0 (CH), 44.9 (CH), 43.6 (CH), 42.3 (C), 38.52 (CH2), 38.49 (CH2), 37.2 (CH2), 35.8 (CH), 35.6 (C), 34.9 (CH), 32.2 (CH2), 31.9 (CH2), 31.2 (CH2), 28.7 (CH2), 28.4 (CH2), 27.6 (CH2), 25.9 (3xCH3), 20.5 (CH2), 18.5 (CH3), 18.2 (C), 16.3 (CH3), 14.6 (CH3), 12.3 (CH3), −4.57 (CH3), −4.59 (CH3); 11B NMR (128 MHz, CDCl3) δ −24.52; ESI-MS 1159 [2M+Na]+. IR ATR, νmax (cm−1): 3468, 2401, 1636, 1458, 1249, 1093, 1056.

3.2.4. Synthesis of Compound 9

To a solution of 4 (19 mg, 0.036 mmol) in dichloromethane (2 mL) at −15 °C, Et3N (0.01 mL, 7.3 mg, 0.072 mmol) and 0.22 mL of solution of MsCl (0.03 mL) in dichloromethane (2 mL) were added, successively. The reaction mixture was continuously stirred at −15 °C for 1.5 h and quenched by adding aqueous NaHCO3, and the layers were separated and the aqueous layer was extracted with chloroform. The organic layers were combined, dried over Na2SO4, and evaporated under reduced pressure. The crude product was purified by column chromatography (20% MeOH/CHCl3) to obtain compound 9 (45%).
Compound 9: 1H NMR (400 MHz, CDCl3) δ 5.45 (m, 1H), 4.25 (m, 1H), 3.61 (m, 1H), 3.13-3.00 (m, 3H), 2.75 (s, 3H), 2.72 (m, 1H), 2.62 (m, 1H), 2.32 (m, 1H), 2.18 (d, J = 6.1, 1H), 1.57 (d, J = 7.1, 3H), 1.08 (d, J = 5.9, 3H), 0.81 (s, 3H), 0.62 (s, 3H); δ 13C NMR (100 MHz, CDCl3) δ 190.6 (C), 75.7 (CH), 71.0 (CH), 57.0 (CH), 54.3 (CH), 54.0 (CH), 52.7 (CH2), 44.6 (CH), 44.5 (CH), 42.0 (C), 39.4 (CH3), 38.2 (CH2), 38.0 (CH2), 36.9 (CH2), 35.5 (C), 35.0 (CH), 32.0 (CH2), 31.3 (CH2), 29.2 (CH2), 28.3 (CH2), 25.84 (CH), 25.82 (CH2), 24.6 (CH2), 20.5 (CH2), 18.2 (CH3), 18.1 (CH3), 14.6 (CH3), 12.3 (CH3); ESI-MS 398 [M+]; IR ATR, νmax (cm−1): 3377, 1664, 1628, 1456, 1195, 1043.

3.2.5. Synthesis of 25-epidemissidine (10)

To the stirred ice-cooled solution of compound 9 (20 mg, 0.04 mmol) in MeOH (2 mL)/DCM (2 mL), NaBH4 (4.6 mg, 0.12 mmol) was added. The stirring of the reaction mixture was continued at −10 – 0 °C for 0.5 h. The reaction mixture was poured into water and extracted with CHCl3. The extract was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated. The crude product was purified by column chromatography (20% AcOEt/hexane) to obtain compound 10 (71%), identical to that described in ref. [21].
Compound 10: 1H NMR (400 MHz, CDCl3): δ 3.60 (m, 1H), 2.59 (m, 2H), 1.03 (d, J = 7.0, 3H), 0.92 (d, J = 6.7, 3H), 0.85 (s, 3H), 0.82 (s, 3H).

3.2.6. Synthesis of Compound 12

Acetyl chloride (0.027 mL, 29 mg, 0.38 mmol) was added to the stirred, ice-cold solution of compound 4 (20 mg, 0.038 mmol) in dry MeOH (3 mL). The reaction mixture was stirred for 3 h and allowed to warm up to room temperature. Then, the solvent was evaporated under reduced pressure and the residue was dissolved in dichloromethane (2 mL) and THF (2 mL). To the obtained suspension, triethylamine (0.02 mL) and 0.58 mL of a solution of MsCl (0.02 mL) in CH2Cl2 (2 mL) were added. The reaction mixture was stirred overnight, allowing it to warm up to room temperature. After this time, the mixture was poured into aqueous NaHCO3 and extracted with CHCl3. The extract was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated. The crude product was purified by column chromatography (35% AcOEt/hexane) to afford compound 12 (53%).
Compound 12: 1H NMR (400 MHz, CDCl3) δ 4.62 (m, 1H), 4.04 (m, 1H), 3.61 (q, J = 7.0, 1H), 3.02 (m, 1H), 3.00 (s, 3H), 2.83 (s, 3H), 2.74 (m, 1H), 2.50 (d, J = 12.5, 1H), 1.24 (d, J = 7.0, 3H), 1.04 (d, J = 6.1, 3H), 0.83 (s, 3H), 0.61 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 160.9 (C), 88.9 (C), 81.6 (CH), 65.4 (CH), 60.5 (CH), 55.0 (CH), 54.1 (CH), 49.0 (CH2), 44.8 (CH), 43.0 (CH3), 41.8 (C), 38.9 (CH3), 38.2 (CH2), 36.7 (CH2), 36.6 (CH), 35.3 (C), 35.1 (CH2), 34.9 (CH), 32.0 (CH2), 30.8 (CH2), 30.7 (CH2), 28.6 (CH2), 28.3 (CH2), 26.8 (CH), 23.0 (CH3), 20.5 (CH2), 18.7 (CH3), 13.5 (CH3), 12.1 (CH3); ESI-MS 554 [M+H]+, 1129 [2M+Na] +. HRMS calculated for C29H48NO5S2 (M+H)+ 554.2968; found 554.2965; IR ATR, νmax (cm−1): 1658, 1453, 1333, 1212, 1163, 1036, 925.

4. Conclusions

In summary, we developed a novel, concise synthesis of solanidanes from the spirostane sapogenin tigogenin. The indolizidine moiety present in solanidane-type alkaloids was constructed from spirostane in five steps involving tigogenin oxidation, amination, reduction, mesylation, and reduction again. The key intermediate for the proposed approach was spiroimine obtained in the reaction of a 5,6-dihydrokrytogenin derivative with aminoalane generated in situ from DIBAlH and NH4Cl. Depending on mesylation conditions, two different solanidanes were obtained: the indolizinium salt 9a, which was readily converted into 25-epidemissidine (10), and the 23-sulfone derivative 12, a convenient intermediate for further derivatization.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ijms221910879/s1, 1H NMR, 13C NMR spectra of compounds 310 and 12.

Author Contributions

Conceptualization, A.W. and J.W.M.; investigation, A.W. and U.K.; methodology, A.W. and A.B.; formal analysis, A.W.; writing—original draft preparation, A.W.; writing—review, editing, and supervising, J.W.M. All authors have read and agreed to the published version of the manuscript.

Funding

The authors acknowledge the financial support from the National Science Centre, Poland (Grant 2015/17/B/ST5/02892).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Attaur, R.; Choudhary, M.I. Diterpenoid and steroidal alkaloids. Nat. Prod. Rep. 1997, 14, 191–203. [Google Scholar] [CrossRef]
  2. Li, H.J.; Jiang, Y.; Li, P. Chemistry, bioactivity and geographical diversity of steroidal alkaloids from the Liliaceae family. Nat. Prod. Rep. 2006, 23, 735–752. [Google Scholar] [CrossRef]
  3. Jiang, Q.-W.; Chen, M.-W.; Cheng, K.-J.; Yu, P.-Z.; Wei, X.; Shi, Z. Therapeutic potential of steroidal alkaloids in cancer and other diseases. Med. Res. Rev. 2016, 36, 119–143. [Google Scholar] [CrossRef] [PubMed]
  4. Friedman, M.; Lee, K.R.; Kim, H.J.; Lee, I.S.; Kozukue, N. Anticarcinogenic effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma, and stomach cancer cells. J. Agric. Food Chem. 2005, 53, 6162–6169. [Google Scholar] [CrossRef] [PubMed]
  5. Lee, K.R.; Kozukue, N.; Han, J.S.; Park, J.H.; Chang, E.Y.; Baek, E.J.; Chang, J.S.; Friedman, M. Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. J. Agric. Food. Chem. 2004, 52, 2832–2839. [Google Scholar] [CrossRef]
  6. Tingey, W.M. Glycoalkaloids as pest resistance factors. Am. J. Potato. Res. 1984, 61, 157–167. [Google Scholar] [CrossRef]
  7. Schreiber, K. Steroid alkaloids: The Solanum group. In The Alkaloids: Chemistry and Physiology; Manske, R.H.F., Ed.; Academic Press: New York, NY, USA, 1968; Volume 10, pp. 1–192. [Google Scholar]
  8. Roddick, J.G. The acetylcholinesterase-inhibitory activity of steroidal glycoalkaloids and their aglycones. Phytochemistry 1989, 28, 2631–2634. [Google Scholar] [CrossRef]
  9. Roddick, J.G.; Weissenberg, M.; Leonard, A.L. Membrane disruption and enzyme inhibition by naturally-occurring and modified chacotriose-containing Solanum steroidal glycoalkaloids. Phytochemistry 2001, 56, 603–610. [Google Scholar] [CrossRef]
  10. Mótyán, G.; Kovács, F.; Wölfling, J.; Gyovai, A.; Zupkó, I.; Frank, É. Microwave-assisted stereoselective approach to novel steroidal ring D-fused 2-pyrazolines and an evaluation of their cell-growth inhibitory effects in vitro. Steroids 2016, 112, 36–46. [Google Scholar] [CrossRef] [PubMed]
  11. Abdalla, M.M.; Al-Omar, M.A.; Bhat, M.A.; Amr, A.-G.E.; Al-Mohizeae, A.M. Steroidal pyrazolines evaluated as aromatase and quinone reductase-2 inhibitors for chemoprevention of cancer. Int. J. Biol. Macromol. 2012, 50, 1127–1132. [Google Scholar] [CrossRef]
  12. Schuster, D.; Wolber, G. Identification of bioactive natural products by pharmacophore-based virtual screening. Curr. Pharm. Des. 2010, 16, 1666–1681. [Google Scholar] [CrossRef] [PubMed]
  13. Kuhn, R.; Low, I.; Trischmann, H. Uberfuhrung von tomatidin in demissidin. Angew. Chem. 1952, 64, 397–397. [Google Scholar] [CrossRef]
  14. Sato, Y.; Latham, H.G. Chemistry of dihydrotomatidines. J. Am. Chem. Soc. 1956, 78, 3146–3150. [Google Scholar] [CrossRef]
  15. Schreiber, K.; Ronsch, H. Solanum-alkaloide-LIV. Synthese von solanidin und 22-iso-solanidin aus tomatid-5-en-3β-ol. Tetrahedron 1965, 21, 645–650. [Google Scholar] [CrossRef]
  16. Adam, G.; Schreiber, K. Synthese des steroid alkaloids demissidin aus 3β-acetoxy-pregn-5-en-20-on; aufbau des solanidine-gerustes durch Hofmann-Loffler-Freytag-cyclisierung. Tetrahedron Lett. 1963, 4, 943–948. [Google Scholar] [CrossRef]
  17. Zhang, Z.; Giampa, G.M.; Draghici, C.; Huang, Q.; Brewer, M. Synthesis of demissidine by a ring fragmentation 1,3-dipolar cycloaddition approach. Org. Lett. 2013, 15, 2100–2103. [Google Scholar] [CrossRef] [Green Version]
  18. Zhang, Z.-D.; Shi, Y.; Wu, J.-J.; Lin, J.-R.; Tian, W.-S. Synthesis of demissidine and solanidine. Org. Lett. 2016, 18, 3038–3040. [Google Scholar] [CrossRef]
  19. Hou, L.-L.; Shi, Y.; Zhang, Z.-D.; Wu, J.-J.; Yang, Q.-X.; Tian, W.-S. Divergent synthesis of solanidine and 22-epi-solanidine. J. Org. Chem. 2017, 82, 7463–7469. [Google Scholar] [CrossRef]
  20. Wang, Y.; Huang, G.; Shi, Y.; Tian, W.-S.; Zhuang, C.; Chen, E.-F. Asymmetric synthesis of (−)-solanidine and (−)-tomatidenol. Org. Biomol. Chem. 2020, 18, 3169–3176. [Google Scholar] [CrossRef]
  21. Rivas-Loaiza, J.A.; Baj, A.; López, Y.; Witkowski, S.; Wojtkielewicz, A.; Morzycki, J.W. Synthesis of solanum alkaloid demissidine stereoisomers and analogues. J. Org. Chem. 2021, 86, 1575–1582. [Google Scholar] [CrossRef]
  22. Cheng, M.S.; Wang, Q.L.; Tian, Q.; Song, Y.H.; Liu, Y.X.; Li, Q.; Xu, X.; Miao, H.D.; Yao, X.S.; Yang, Z. Total synthesis of methyl protodioscin: A potent agent with antitumor activity. J. Org. Chem. 2003, 68, 3658–3662. [Google Scholar] [CrossRef] [PubMed]
  23. Lee, J.S.; Cao, H.; Fuchs, P.L. Ruthenium-catalyzed mild C–H oxyfunctionalization of cyclic steroidal ethers. J. Org. Chem. 2007, 72, 5820–5823. [Google Scholar] [CrossRef] [PubMed]
  24. Yu, B.; Liao, J.; Zhang, J.; Hui, Y. The first synthetic route to furostan saponins. Tetrahedron Lett. 2001, 42, 77–79. [Google Scholar] [CrossRef]
  25. Bovicelli, P.; Lupettelli, P.; Fracas, D. Sapogenins and dimethyldioxirane: A new entry to cholestanes functionalized at the side chain. Tetrahedron Lett. 1994, 35, 935–938. [Google Scholar] [CrossRef]
  26. Overman, L.E.; Sugai, S. A Convenient Method for obtaining trans-2-aminocyclohexanol and trans-2-aminocyclopentanol in enantiomerically pure form. J. Org. Chem. 1985, 50, 4154–4155. [Google Scholar] [CrossRef]
  27. Overman, L.E.; Flippin, L.A. Facile aminolysis of epoxides with diethylaluminum amides. Tetrahedron Lett. 1981, 22, 195–198. [Google Scholar] [CrossRef]
  28. Ashworth, I.W.; Bowden, M.C.; Dembofsky, B.; Levin, D.; Moss, W.; Robinson, E.; Szczur, N.; Virica, J. A new route for manufacture of 3-cyano-1-naphthalenecarboxylic acid. Org. Process. Res. Dev. 2003, 7, 74–81. [Google Scholar] [CrossRef]
  29. Veerasamy, N.; Carlson, E.C.; Collett, N.D.; Saha, M.; Carter, R.G. Enantioselective approach to quinolizidines: Total synthesis of cermizine D and formal syntheses of senepodine G and cermizine C. J. Org. Chem. 2013, 78, 4779–4800. [Google Scholar] [CrossRef] [Green Version]
  30. Bakunova, S.M.; Bakunov, S.A.; Wenzler, T.; Barszcz, T.; Werbovetz, K.A.; Brun, R.; Hall, J.E.; Tidwell, R.R. Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations. J. Med. Chem. 2007, 50, 5807–5823. [Google Scholar] [CrossRef]
  31. Huang, S.-Q.; Zheng, X.; Deng, X.-M. DIBAL-H-H2NR and DIBAL-H-HNR1R2·HCl complexes for efficient conversion of lactones and esters to amides. Tetrahedron Lett. 2001, 42, 9039–9041. [Google Scholar] [CrossRef]
  32. Wojtkielewicz, A.; Łotowski, Z.; Morzycki, J.W. One-step synthesis of nitriles from acids, esters and amides using DIBAL-H and ammonium chloride. Synlett 2015, 26, 2288–2292. [Google Scholar] [CrossRef]
  33. Bechara, W.S.; Charette, A.B.; Na, R.; Wang, W.; Zheng, C. Diethyl 1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. In Encyclopedia of Reagents for Organic Synthesis 2020; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2020. [Google Scholar] [CrossRef]
  34. Czajkowska-Szczykowska, D.; Jastrzebska, I.; Rode, J.E.; Morzycki, J.W. Revision of the structure of N,O-diacetylsolasodine. Unusual epimerization at the spiro carbon atom during acetylation of solasodine. J. Nat. Prod. 2019, 82, 59–65. [Google Scholar] [CrossRef]
  35. Chagnon, F.; Guay, I.; Bonin, M.-A.; Mitchell, G.; Bouarab, K.; Malouin, F.; Marsault, É. Unraveling the structure-reactivity relationship of tomatidine, a steroid alkaloid with unique antibiotic properties against persistent forms of Staphylococcus aureus. Eur. J. Med. Chem. 2014, 80, 605–620. [Google Scholar] [CrossRef]
  36. Zha, X.M.; Zhang, F.R.; Shan, J.Q.; Zhang, Y.H.; Liu, J.O.; Sun, H.B. Synthesis and evaluation of in vitro anticancer activity of novel solasodine derivatives. Chin. Chem. Lett. 2010, 21, 1087–1090. [Google Scholar] [CrossRef]
  37. Uhle, F.C.; Sallmann, F. The synthesis and transformations of a steroid pyrroline Derivative. J. Am. Chem. Soc. 1960, 82, 1190–1199. [Google Scholar] [CrossRef]
  38. Reddy, C.R.; Ramesh, P.; Latha, B. Formal syntheses of 5,8-disubstituted indolizidine alkaloids (–)-205A, (–)-207A, and (–)-235B. Synlett 2016, 27, 481–484. [Google Scholar] [CrossRef]
  39. Donohoe, T.J.; Sintim, H.O.; Hollinshead, J. A Noncarbohydrate Based Approach to Polyhydroxylated. J. Org. Chem. 2005, 70, 7297–7304. [Google Scholar] [CrossRef]
  40. Mátyus, P.; Szilágyi, G.; Kasztreiner, E.; Sohár, P. Studies on pyridazine derivatives. IV. Mesylation reaction of pyridazinylpyrazoles. J. Heterocycl. Chem. 1980, 17, 781–783. [Google Scholar] [CrossRef]
  41. Back, T.G.; Hu, N.-X. Synthesis of Antibiotic A25822 B. Tetrahedron 1993, 49, 337–348. [Google Scholar] [CrossRef]
  42. Cheng, S.; Du, Y.; Mac, B.; Tanc, D. Total synthesis of a furostan saponin, timosaponin BII. Org. Biomol. Chem. 2009, 7, 3112–3118. [Google Scholar] [CrossRef]
Figure 1. Steroidal alkaloids of solanidane type.
Figure 1. Steroidal alkaloids of solanidane type.
Ijms 22 10879 g001
Scheme 1. Synthesis of spiroimine 3 from tigogenin 3-TBS ether (1).
Scheme 1. Synthesis of spiroimine 3 from tigogenin 3-TBS ether (1).
Ijms 22 10879 sch001
Scheme 2. Reduction of imine 3 with borohydrides.
Scheme 2. Reduction of imine 3 with borohydrides.
Ijms 22 10879 sch002
Figure 2. Complex 8 formed during the imine 3 reduction with NaBH3CN/AcOH.
Figure 2. Complex 8 formed during the imine 3 reduction with NaBH3CN/AcOH.
Ijms 22 10879 g002
Scheme 3. Synthesis of 25-epidemissidine (10).
Scheme 3. Synthesis of 25-epidemissidine (10).
Ijms 22 10879 sch003
Figure 3. Major products of imine 4 mesylation under harsh conditions.
Figure 3. Major products of imine 4 mesylation under harsh conditions.
Ijms 22 10879 g003
Scheme 4. Mesylation of imine 4 preceded by protonation with HCl.
Scheme 4. Mesylation of imine 4 preceded by protonation with HCl.
Ijms 22 10879 sch004
Scheme 5. Tentative mechanism of sulfone 12 formation from imine 4.
Scheme 5. Tentative mechanism of sulfone 12 formation from imine 4.
Ijms 22 10879 sch005
Table 1. The optimization of imine 3 reduction conditions.
Table 1. The optimization of imine 3 reduction conditions.
Ijms 22 10879 i001
EntryReagent
(equiv.)
ConditionsProduct 4 Yield (%)Product 7 Yield (%)Substrate
Recovery (%)
1NaBH4 (2)MeOH/CH2Cl2,
−18 °C, 1 h
6430<1
2NaBH4 (1)MeOH/CH2Cl2,
−18 °C, 1 h
58<521
3NaBH4 (1)MeOH/CH2Cl2,
0 °C, 1 h
6713<5
4NaBH4 (1)NaOAc (1 equiv.),
MeOH/CH2Cl2,
0 °C–room temp., 2 h
65<530
5NaBH4 (4)I2 (4 equiv.),
MeOH/ CH2Cl2,
0 °C–reflux, 16 h
789<1
6NaBH3CN (2)AcOH (2 equiv.),
THF, room temp., 1 h
complex
8 (48)
nd *<5
7NaBH3CN (2)THF/MeOH, room temp., 2 h28nd *30
* nd—not detected.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Wojtkielewicz, A.; Kiełczewska, U.; Baj, A.; Morzycki, J.W. Synthesis of Demissidine Analogues from Tigogenin via Imine Intermediates. Int. J. Mol. Sci. 2021, 22, 10879. https://doi.org/10.3390/ijms221910879

AMA Style

Wojtkielewicz A, Kiełczewska U, Baj A, Morzycki JW. Synthesis of Demissidine Analogues from Tigogenin via Imine Intermediates. International Journal of Molecular Sciences. 2021; 22(19):10879. https://doi.org/10.3390/ijms221910879

Chicago/Turabian Style

Wojtkielewicz, Agnieszka, Urszula Kiełczewska, Aneta Baj, and Jacek W. Morzycki. 2021. "Synthesis of Demissidine Analogues from Tigogenin via Imine Intermediates" International Journal of Molecular Sciences 22, no. 19: 10879. https://doi.org/10.3390/ijms221910879

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop